Payment overview · 2025
General Payments
$994.43
64 reported records · 12 companies
Healthcare provider profile · identity verified
Mark L. Davis, P.A.-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · SHAWNEE, OK · NPI 1487747713
Verified facts
What the public records show
CMS Open Payments records show Mark L. Davis, P.A.-C received $994.43 in general payments during 2025 across 64 reported records.
GlaxoSmithKline, LLC. accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 807 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $199.59 | 20.1% | 20 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $158.33 | 15.9% | 10 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $155.08 | 15.6% | 10 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $152.24 | 15.3% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.40 | 7.9% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $67.35 | 6.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.70 | 5.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.33 | 4.1% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $29.85 | 3.0% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $27.90 | 2.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.93 | 1.5% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $14.73 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $994.43 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $219.59 | 9 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $172.04 | 17 | 2025 |
Source payment records
|
|||||
| Hillrom - Monarch Airway Clearance System Normalized: hillrom monarch airway clearance system |
Device | Baxter Healthcare | $158.33 | 10 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $155.08 | 10 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $78.40 | 4 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $55.70 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $29.85 | 2 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $27.90 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.55 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 807 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
118 | 43 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
807 | 179 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 824 | 224 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 807 | 179 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 620 | 237 |
| Prednisone | Prednisone | 351 | 174 |
| Azithromycin | Azithromycin | 310 | 120 |
| Fluticasone Propionate | Fluticasone Propionate | 268 | 92 |
| Omeprazole | Omeprazole | 247 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 226 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 220 | 56 |
| Gabapentin | Gabapentin | 218 | 54 |
| Famotidine | Famotidine | 217 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 57 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 190 | 63 |
| Lisinopril | Lisinopril | 161 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 151 | 49 |
| Losartan Potassium | Losartan Potassium | 151 | 44 |
| Symbicort | Budesonide/Formoterol Fumarate | 118 | 43 |
| Ventolin Hfa | Albuterol Sulfate | 113 | 44 |
| Torsemide | Torsemide | 112 | 31 |
| Spiriva Respimat | Tiotropium Bromide | 102 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 93 | 30 |
| Alprazolam | Alprazolam | 92 | 22 |
| Furosemide | Furosemide | 90 | 30 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 85 | 29 |
| Cefuroxime | Cefuroxime Axetil | 84 | 59 |
| Breo Ellipta | Fluticasone/Vilanterol | 79 | 22 |
| Spiriva Handihaler | Tiotropium Bromide | 78 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 73 | 22 |
| Carvedilol | Carvedilol | 72 | 20 |
| Simvastatin | Simvastatin | 71 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 69 | 22 |
| Tramadol Hcl | Tramadol Hcl | 68 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 14 |
| Eliquis | Apixaban | 63 | 17 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 62 | 13 |
| Potassium Chloride | Potassium Chloride | 62 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 12 |
| Allopurinol | Allopurinol | 55 | 16 |
| Metformin Hcl Er | Metformin Hcl | 55 | 17 |
| Azelastine Hcl | Azelastine Hcl | 51 | 19 |
| Glipizide Er | Glipizide | 49 | 14 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 47 | 20 |
| Trulicity | Dulaglutide | 47 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 46 | 12 |
| Glimepiride | Glimepiride | 44 | 13 |
| Ozempic | Semaglutide | 44 | 12 |
| Levofloxacin | Levofloxacin | 43 | 34 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 38 | 14 |
| Diazepam | Diazepam | 37 | 15 |
| Meloxicam | Meloxicam | 37 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 11 |
| Sertraline Hcl | Sertraline Hcl | 36 | 12 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 35 | 11 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Metformin Hcl | Metformin Hcl | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Dulera | Mometasone/Formoterol | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | 11 |
| Atenolol | Atenolol | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 22 |
| Fluconazole | Fluconazole | 25 | 17 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 23 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Dupixent Pen | Dupilumab | 13 | suppressed |
| Fasenra Pen | Benralizumab | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $994.43 · 64 records | GlaxoSmithKline, LLC. | DUPIXENT, FASENRA, Hillrom - Monarch Airway Clearance System, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JASCAYD, NUCALA, NURTEC ODT, OFEV, Ohtuvayre, TEZSPIRE, TRELEGY ELLIPTA, Vest Therapy Und, YUPELRI, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error